Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
221.32
-1.19 (-0.53%)
At close: May 8, 2026, 4:00 PM EDT
221.25
-0.07 (-0.03%)
After-hours: May 8, 2026, 7:59 PM EDT
Johnson & Johnson Employees
Johnson & Johnson had 138,200 employees as of December 31, 2025. The number of employees increased by 100 or 0.07% compared to the previous year.
Employees
138,200
Change (1Y)
100
Growth (1Y)
0.07%
Revenue / Employee
$697,265
Profits / Employee
$152,243
Market Cap
532.77B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 138,200 | 100 | 0.07% |
| Dec 31, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Dec 31, 2022 | 152,700 | 11,000 | 7.76% |
| Dec 31, 2021 | 141,700 | 7,200 | 5.35% |
| Dec 31, 2020 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | 132,200 | -2,900 | -2.15% |
| Dec 30, 2018 | 135,100 | 1,100 | 0.82% |
| Dec 31, 2017 | 134,000 | 7,600 | 6.01% |
| Dec 31, 2016 | 126,400 | -700 | -0.55% |
| Dec 31, 2015 | 127,100 | 600 | 0.47% |
| Dec 28, 2014 | 126,500 | -1,600 | -1.25% |
| Dec 29, 2013 | 128,100 | 500 | 0.39% |
| Dec 30, 2012 | 127,600 | 9,700 | 8.23% |
| Dec 31, 2011 | 117,900 | 3,900 | 3.42% |
| Dec 31, 2010 | 114,000 | -1,500 | -1.30% |
| Dec 31, 2009 | 115,500 | -3,200 | -2.70% |
| Dec 28, 2008 | 118,700 | -500 | -0.42% |
| Dec 30, 2007 | 119,200 | -3,000 | -2.45% |
| Dec 31, 2006 | 122,200 | 6,600 | 5.71% |
| Dec 31, 2005 | 115,600 | 5,600 | 5.09% |
| Dec 31, 2004 | 110,000 | -1,000 | -0.90% |
| Dec 28, 2003 | 111,000 | 3,000 | 2.78% |
| Dec 29, 2002 | 108,000 | 6,000 | 5.88% |
| Dec 30, 2001 | 102,000 | 1,000 | 0.99% |
| Dec 31, 2000 | 101,000 | 3,200 | 3.27% |
| Dec 31, 1999 | 97,800 | 4,700 | 5.05% |
| Dec 31, 1998 | 93,100 | 2,600 | 2.87% |
| Dec 28, 1997 | 90,500 | 1,200 | 1.34% |
| Dec 29, 1996 | 89,300 | 7,000 | 8.51% |
| Dec 31, 1995 | 82,300 | 800 | 0.98% |
| Dec 31, 1994 | 81,500 | -100 | -0.12% |
| Dec 31, 1993 | 81,600 | -3,300 | -3.89% |
| Dec 31, 1992 | 84,900 | 2,200 | 2.66% |
| Dec 31, 1991 | 82,700 | 500 | 0.61% |
| Dec 31, 1990 | 82,200 | -900 | -1.08% |
| Dec 31, 1989 | 83,100 | 1,800 | 2.21% |
| Dec 31, 1988 | 81,300 | 3,100 | 3.96% |
| Dec 31, 1987 | 78,200 | 1,100 | 1.43% |
| Dec 31, 1986 | 77,100 | 2,200 | 2.94% |
| Dec 31, 1985 | 74,900 | 700 | 0.94% |
| Dec 31, 1984 | 74,200 | -3,200 | -4.13% |
| Dec 31, 1983 | 77,400 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| AbbVie | 57,000 |
| Eli Lilly and Company | 50,000 |
JNJ News
- 2 days ago - This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J - Barrons
- 2 days ago - Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission - PRNewsWire
- 4 days ago - CVS to drop J&J's Stelara from its main formularies - Reuters
- 4 days ago - Johnson & Johnson announces results from Phase 3 FUZION study of tremfya - TheFly
- 4 days ago - Johnson & Johnson announces Phase 2b data from JNJ-4804 studies - TheFly
- 4 days ago - Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease - PRNewsWire
- 4 days ago - Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease - PRNewsWire
- 4 days ago - Johnson & Johnson announces study of OTTAVA System met primary endpoints - TheFly